Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mammography | 26 | 2023 | 1010 | 2.790 |
Why?
|
| Breast Neoplasms | 38 | 2024 | 15706 | 2.030 |
Why?
|
| Radiographic Image Enhancement | 9 | 2014 | 403 | 1.720 |
Why?
|
| Papilloma, Intraductal | 2 | 2020 | 16 | 1.510 |
Why?
|
| Calcinosis | 7 | 2019 | 425 | 1.430 |
Why?
|
| Mucocele | 2 | 2019 | 22 | 1.390 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2020 | 675 | 1.160 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2020 | 137 | 1.040 |
Why?
|
| Ultrasonography, Mammary | 10 | 2022 | 381 | 1.000 |
Why?
|
| Breast | 8 | 2022 | 1350 | 1.000 |
Why?
|
| Breast Diseases | 5 | 2024 | 201 | 0.930 |
Why?
|
| Margins of Excision | 2 | 2022 | 285 | 0.740 |
Why?
|
| Image-Guided Biopsy | 6 | 2022 | 327 | 0.740 |
Why?
|
| Esthetics | 1 | 2021 | 189 | 0.730 |
Why?
|
| Carcinoma, Ductal, Breast | 5 | 2019 | 1218 | 0.710 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 1026 | 0.700 |
Why?
|
| Machine Learning | 1 | 2021 | 320 | 0.670 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2023 | 1215 | 0.630 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 436 | 0.530 |
Why?
|
| Radiology | 3 | 2021 | 434 | 0.500 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2011 | 362 | 0.490 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 927 | 0.470 |
Why?
|
| Decision Making | 4 | 2019 | 1294 | 0.460 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 1266 | 0.370 |
Why?
|
| Sensitivity and Specificity | 11 | 2016 | 4978 | 0.360 |
Why?
|
| Clinical Competence | 4 | 2021 | 1306 | 0.350 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 164 | 0.350 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 126 | 0.350 |
Why?
|
| Gynecomastia | 1 | 2008 | 13 | 0.340 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 7728 | 0.330 |
Why?
|
| Carcinoma, Lobular | 3 | 2021 | 613 | 0.330 |
Why?
|
| Female | 44 | 2024 | 142232 | 0.330 |
Why?
|
| Forecasting | 1 | 2011 | 695 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 11 | 2023 | 4980 | 0.310 |
Why?
|
| User-Computer Interface | 1 | 2009 | 286 | 0.310 |
Why?
|
| Axilla | 5 | 2023 | 903 | 0.300 |
Why?
|
| Breast Neoplasms, Male | 1 | 2008 | 229 | 0.300 |
Why?
|
| Humans | 53 | 2024 | 262185 | 0.290 |
Why?
|
| Retrospective Studies | 15 | 2024 | 38007 | 0.280 |
Why?
|
| Carcinoma in Situ | 2 | 2006 | 485 | 0.280 |
Why?
|
| Medical Staff, Hospital | 1 | 2006 | 120 | 0.270 |
Why?
|
| Observer Variation | 6 | 2014 | 672 | 0.250 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 593 | 0.230 |
Why?
|
| Lymphatic Metastasis | 5 | 2023 | 4847 | 0.230 |
Why?
|
| Biopsy | 4 | 2022 | 3455 | 0.230 |
Why?
|
| Precancerous Conditions | 3 | 2011 | 1063 | 0.220 |
Why?
|
| Radiation Dosage | 3 | 2016 | 1016 | 0.220 |
Why?
|
| X-Ray Film | 2 | 2009 | 31 | 0.210 |
Why?
|
| Algorithms | 3 | 2011 | 3891 | 0.210 |
Why?
|
| Hyperplasia | 1 | 2003 | 559 | 0.200 |
Why?
|
| Stereotaxic Techniques | 2 | 2017 | 172 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 1163 | 0.190 |
Why?
|
| Mass Screening | 3 | 2011 | 1505 | 0.180 |
Why?
|
| Iodine Radioisotopes | 1 | 2022 | 373 | 0.180 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2519 | 0.180 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2020 | 158 | 0.170 |
Why?
|
| Radiographic Magnification | 1 | 2009 | 14 | 0.170 |
Why?
|
| Mastectomy | 3 | 2024 | 1538 | 0.170 |
Why?
|
| Fat Necrosis | 1 | 2009 | 63 | 0.160 |
Why?
|
| Artifacts | 1 | 2011 | 532 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2022 | 1529 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 89 | 0.160 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 137 | 0.160 |
Why?
|
| Adult | 14 | 2021 | 78082 | 0.160 |
Why?
|
| Workload | 1 | 2009 | 199 | 0.150 |
Why?
|
| Middle Aged | 19 | 2021 | 86445 | 0.150 |
Why?
|
| Lymph Node Excision | 3 | 2023 | 1960 | 0.150 |
Why?
|
| Reproducibility of Results | 7 | 2018 | 6038 | 0.140 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 430 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2023 | 1417 | 0.140 |
Why?
|
| Surgical Instruments | 1 | 2017 | 138 | 0.140 |
Why?
|
| Prognosis | 6 | 2019 | 21745 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 117 | 0.140 |
Why?
|
| Prospective Studies | 8 | 2023 | 12915 | 0.130 |
Why?
|
| Histiocytosis, Sinus | 1 | 2005 | 86 | 0.120 |
Why?
|
| Lymph Nodes | 3 | 2023 | 2968 | 0.120 |
Why?
|
| Ultrasonography | 4 | 2023 | 1866 | 0.110 |
Why?
|
| Nipples | 2 | 2024 | 132 | 0.110 |
Why?
|
| Aged | 13 | 2023 | 70323 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2023 | 13672 | 0.110 |
Why?
|
| ROC Curve | 3 | 2014 | 1180 | 0.100 |
Why?
|
| Biopsy, Needle | 3 | 2017 | 1364 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2021 | 1411 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 14902 | 0.090 |
Why?
|
| Time Factors | 3 | 2016 | 12969 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 341 | 0.080 |
Why?
|
| Treatment Outcome | 4 | 2023 | 32986 | 0.080 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 253 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2018 | 3891 | 0.080 |
Why?
|
| Genital Neoplasms, Male | 1 | 2006 | 44 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2023 | 2802 | 0.070 |
Why?
|
| Chromosome Inversion | 1 | 2006 | 182 | 0.070 |
Why?
|
| Sarcoma, Myeloid | 1 | 2006 | 93 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 4755 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2006 | 254 | 0.060 |
Why?
|
| Contrast Media | 2 | 2022 | 1475 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 691 | 0.060 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2003 | 46 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2018 | 2300 | 0.050 |
Why?
|
| Magnetic Phenomena | 1 | 2022 | 26 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 5713 | 0.050 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14300 | 0.050 |
Why?
|
| Pulmonary Fibrosis | 1 | 2002 | 170 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2011 | 301 | 0.050 |
Why?
|
| Whole Body Imaging | 1 | 2020 | 114 | 0.040 |
Why?
|
| Phantoms, Imaging | 2 | 2008 | 1275 | 0.040 |
Why?
|
| Radiology Information Systems | 1 | 2010 | 114 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 29997 | 0.040 |
Why?
|
| Anthracyclines | 1 | 2021 | 331 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 585 | 0.040 |
Why?
|
| United States | 1 | 2016 | 15561 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2022 | 548 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1329 | 0.040 |
Why?
|
| Calcification, Physiologic | 1 | 2008 | 54 | 0.040 |
Why?
|
| Professional Competence | 1 | 2009 | 136 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 970 | 0.040 |
Why?
|
| Linear Models | 1 | 2010 | 1090 | 0.040 |
Why?
|
| Mammary Glands, Human | 1 | 2008 | 184 | 0.040 |
Why?
|
| Internet | 1 | 2021 | 712 | 0.040 |
Why?
|
| Curriculum | 1 | 2021 | 864 | 0.030 |
Why?
|
| Young Adult | 2 | 2017 | 21473 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2017 | 6892 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1992 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 273 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 15874 | 0.030 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2006 | 2342 | 0.030 |
Why?
|
| Software | 1 | 2010 | 1325 | 0.030 |
Why?
|
| Data Display | 1 | 2002 | 49 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2745 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2002 | 329 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 2333 | 0.020 |
Why?
|
| Video Recording | 1 | 2002 | 266 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1303 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2059 | 0.020 |
Why?
|
| Models, Biological | 1 | 2008 | 3249 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 10355 | 0.020 |
Why?
|
| Texas | 1 | 2009 | 6308 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 4903 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 3752 | 0.020 |
Why?
|
| Snake Bites | 1 | 1966 | 8 | 0.020 |
Why?
|
| Antivenins | 1 | 1966 | 9 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 5436 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 9294 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2006 | 566 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1033 | 0.010 |
Why?
|
| Idarubicin | 1 | 2006 | 446 | 0.010 |
Why?
|
| Male | 4 | 2008 | 123269 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 7793 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2003 | 52 | 0.010 |
Why?
|
| Respiratory Insufficiency | 1 | 1966 | 330 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 414 | 0.010 |
Why?
|
| Cytarabine | 1 | 2006 | 1973 | 0.010 |
Why?
|
| Remission Induction | 1 | 2006 | 3576 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 11575 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3987 | 0.010 |
Why?
|
| Radiography | 1 | 2002 | 1910 | 0.010 |
Why?
|
| Sex Factors | 1 | 2002 | 2156 | 0.010 |
Why?
|
| Logistic Models | 1 | 2003 | 3450 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 10009 | 0.010 |
Why?
|
| Smoking | 1 | 2002 | 2444 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 5385 | 0.010 |
Why?
|
| Tetanus Antitoxin | 1 | 1966 | 2 | 0.000 |
Why?
|
| Paralysis | 1 | 1966 | 51 | 0.000 |
Why?
|
| Hyperbaric Oxygenation | 1 | 1966 | 48 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 17606 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1966 | 585 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1966 | 2995 | 0.000 |
Why?
|
| Adolescent | 1 | 1966 | 31247 | 0.000 |
Why?
|
| Child | 1 | 1966 | 29127 | 0.000 |
Why?
|